Article PDF first page preview

Article PDF first page preview

Complement-mediated thrombotic microangiopathy (CM-TMA) is a rare and life-threatening complication that can occur in kidney transplant recipients, with various potential triggers including immunosuppressive medications. The optimal management and duration of treatment with C5 inhibitors (C5i) for CM-TMA in this patient population remain areas of ongoing investigation. We present the case of a 38-year-old female with a history of IgA nephropathy who underwent preemptive living-related kidney transplantation and subsequently developed CM-TMA 7 years post-transplant. Treatment with ravulizumab led to a rapid hematologic response and stabilized platelet counts. Serial measurements of complement functional tests and clinical stability guided the discontinuation of C5i therapy. The case highlights the complexity of managing CM-TMA in kidney transplant recipients, particularly in determining the appropriate duration of C5i therapy. The absence of an established protocol for discontinuation necessitates a personalized approach based on clinical and laboratory stability, absence of complement gene variants, and serial complement functional tests. Further prospective investigations are warranted to define the optimal strategies for monitoring and safely discontinuing C5i therapy in this unique patient population. This case underscores the importance of individualized care in the management of CM-TMA post-kidney transplantation, offering insights into potential criteria for therapy discontinuation.

1.
Noris
M
,
Remuzzi
G
.
Atypical hemolytic–uremic syndrome
.
N Engl J Med
.
2009
;
361
(
17
):
1676
87
.
2.
Von Tokarski
F
,
Fillon
A
,
Maisons
V
,
Thoreau
B
,
Bayer
G
,
Gatault
P
, et al
.
Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology
.
BMC Nephrol
.
2023
;
24
(
1
):
278
.
3.
Leon
J
,
LeStang
M
,
Sberro-Soussan
R
,
Servais
A
,
Anglicheau
D
,
Frémeaux-Bacchi
V
, et al
.
Complement-driven hemolytic uremic syndrome
.
Am J Hematol
.
2023
;
98
(
Suppl 4
):
S44
56
.
4.
Fakhouri
F
,
Hourmant
M
,
Campistol
JM
,
Cataland
SR
,
Espinosa
M
,
Gaber
AO
, et al
.
Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial
.
Am J Kidney Dis
.
2016
;
68
(
1
):
84
93
.
5.
Macia
M
,
de Alvaro Moreno
F
,
Dutt
T
,
Fehrman
I
,
Hadaya
K
,
Gasteyger
C
, et al
.
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
.
Clin Kidney J
.
2017
;
10
(
3
):
sfw115
.
6.
Noris
M
,
Remuzzi
G
.
Thrombotic microangiopathy after kidney transplantation
.
Am J Transpl
.
2010
;
10
(
7
):
1517
23
.
7.
Garg
N
,
Rennke
HG
,
Pavlakis
M
,
Zandi-Nejad
K
.
De novo thrombotic microangiopathy after kidney transplantation
.
Transpl Rev
.
2018
;
32
(
1
):
58
68
.
8.
Le Quintrec
M
,
Lionet
A
,
Kamar
N
,
Karras
A
,
Barbier
S
,
Buchler
M
, et al
.
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation
.
Am J Transpl
.
2008
;
8
(
8
):
1694
701
.
9.
Chua
JS
,
Baelde
HJ
,
Zandbergen
M
,
Wilhelmus
S
,
van Es
LA
,
de Fijter
JW
, et al
.
Complement factor C4d is a common denominator in thrombotic microangiopathy
.
J Am Soc Nephrol
.
2015
;
26
(
9
):
2239
47
.
10.
Reynolds
JC
,
Agodoa
LY
,
Yuan
CM
,
Abbott
KC
.
Thrombotic microangiopathy after renal transplantation in the United States
.
Am J Kidney Dis
.
2003
;
42
(
5
):
1058
68
.
11.
Fortin
MC
,
Raymond
MA
,
Madore
F
,
Fugère
J-A
,
Pâquet
M
,
St-Louis
G
, et al
.
Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin–sirolimus combination
.
Am J Transpl
.
2004
;
4
(
6
):
946
52
.
12.
Legendre
CM
,
Licht
C
,
Muus
P
,
Greenbaum
LA
,
Babu
S
,
Bedrosian
C
, et al
.
Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome
.
N Engl J Med
.
2013
;
368
(
23
):
2169
81
.
13.
Imanifard
Z
,
Liguori
L
,
Remuzzi
G
.
TMA in kidney transplantation
.
Transplantation
.
2023
;
107
(
11
):
2329
40
.
14.
Cugno
M
,
Gualtierotti
R
,
Possenti
I
,
Testa
S
,
Tel
F
,
Griffini
S
, et al
.
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
.
J Thromb Haemost
.
2014
;
12
(
9
):
1440
8
.
15.
Ardissino
G
,
Tel
F
,
Sgarbanti
M
,
Cresseri
D
,
Giussani
A
,
Griffini
S
, et al
.
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update
.
Pediatr Nephrol
.
2018
;
33
(
3
):
457
61
.
16.
Fakhouri
F
,
Fila
M
,
Hummel
A
,
Ribes
D
,
Sellier-Leclerc
AL
,
Ville
S
, et al
.
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study
.
Blood
.
2021
;
137
(
18
):
2438
49
.
17.
Chaturvedi
S
,
Dhaliwal
N
,
Hussain
S
,
Dane
K
,
Upreti
H
,
Braunstein
EM
, et al
.
Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome
.
Blood Adv
.
2021
;
5
(
5
):
1504
12
.
18.
Bouwmeester
RN
,
Duineveld
C
,
Wijnsma
KL
,
Bemelman
FJ
,
van der Heijden
JW
,
van Wijk
JAE
, et al
.
Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study
.
Kidney Int Rep
.
2023
;
8
(
1
):
91
102
.
You do not currently have access to this content.